Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 1
2014 2
2015 2
2016 1
2017 2
2018 1
2019 1
2020 4
2021 1
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. You B, et al. Among authors: colomban o. J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Epub 2022 Oct 17. J Clin Oncol. 2022. PMID: 36252167 Free PMC article. Clinical Trial.
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O. You B, et al. Among authors: colomban o. Clin Cancer Res. 2020 Sep 1;26(17):4625-4632. doi: 10.1158/1078-0432.CCR-20-0054. Epub 2020 Mar 24. Clin Cancer Res. 2020. PMID: 32209570 Clinical Trial.
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A. Corbaux P, et al. Among authors: colomban o. Eur J Cancer. 2023 Sep;191:112966. doi: 10.1016/j.ejca.2023.112966. Epub 2023 Jul 4. Eur J Cancer. 2023. PMID: 37542936 Free article.
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.
Lauby A, Colomban O, Corbaux P, Peron J, Van Wagensveld L, Gertych W, Bakrin N, Descargues P, Lopez J, Kepenekian V, Glehen O, Philip CA, Devouassoux-Shisheboran M, Tod M, Freyer G, You B. Lauby A, et al. Among authors: colomban o. Cancers (Basel). 2021 Dec 25;14(1):98. doi: 10.3390/cancers14010098. Cancers (Basel). 2021. PMID: 35008262 Free PMC article. Review.
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O, Swisher EM, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, Lin KK, Maloney L, Freyer G, You B. Colomban O, et al. EBioMedicine. 2023 Mar;89:104477. doi: 10.1016/j.ebiom.2023.104477. Epub 2023 Feb 16. EBioMedicine. 2023. PMID: 36801617 Free PMC article.
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
You B, Van Wagensveld L, Tod M, Sonke GS, Horlings HM, Kruitwagen RFPM, Du Bois A, Selle F, Perren T, Pfisterer J, Joly F, Cook A, Kaminsky MC, Wollschlaeger K, Lortholary A, Tome O, Leary A, Freyer G, Van Der Aa M, Colomban O. You B, et al. Among authors: colomban o. Br J Cancer. 2022 Jul;127(1):79-83. doi: 10.1038/s41416-022-01732-7. Epub 2022 Mar 31. Br J Cancer. 2022. PMID: 35361918 Free PMC article.
Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
Le Saux O, Bourmaud A, Rioufol C, Colomban O, Guitton J, Schwiertz V, Regnier V, You B, Ranchon F, Maraval-Gaget R, Girard P, Chauvin F, Freyer G, Tod M, Henin E, Trillet-Lenoir V. Le Saux O, et al. Among authors: colomban o. Cancer Chemother Pharmacol. 2018 Aug;82(2):319-327. doi: 10.1007/s00280-018-3612-x. Epub 2018 Jun 15. Cancer Chemother Pharmacol. 2018. PMID: 29948022
26 results